BC Extra | Jul 31, 2019
Company News

Apelian to lead new T cell company BlueSphere

With serial biotech executive David Apelian as CEO, University of Pittsburgh and UPMC spinout BlueSphere debuted Wednesday with plans to move its personalized T cell therapies into the clinic. Pitt professors Mark and Warren Shlomchik,...
BC Extra | Nov 18, 2016
Company News

Gilead ends GlobeImmune HBV deal

GlobeImmune Inc. (Pink:GMIB) said Gilead Sciences Inc. (NASDAQ:GILD) returned rights to HBV candidate GS-4774 and terminated a 2011 partnership to develop HBV vaccines. The companies had hoped to create vaccines based on GlobeImmune's Tarmogen products,...
BC Week In Review | Nov 18, 2016
Company News

Gilead, GlobeImmune deal

GlobeImmune said Gilead terminated a 2011 deal granting Gilead rights to GS-4774 . GlobeImmune regained all rights to the product. GS-4774, a Tarmogen comprising a heat-inactivated Saccharomyces cerevisiae that expresses HBV antigens, missed the primary endpoint...
BC Week In Review | Sep 21, 2015
Company News

GlobeImmune cancer news

In August, GlobeImmune hired Cantor Fitzgerald & Co. to evaluate strategic options, including a merger or sale of all or part of the company. Earlier this year, Celgene Corp. (NASDAQ:CELG, Summit, N.J.) exercised its option...
BC Week In Review | Aug 10, 2015
Company News

GlobeImmune, Celgene deal

Celgene exercised its option under an 2009 deal and received exclusive, worldwide rights to oncology candidate GI-6207 from GlobeImmune. GlobeImmune will receive a $1.9 million option exercise fee and is eligible for undisclosed regulatory and...
BC Extra | Aug 4, 2015
Company News

Celgene licenses GlobeImmune cancer candidate

Celgene Corp. (NASDAQ:CELG) exercised its option to license exclusive, worldwide rights to oncology candidate GI-6207 from GlobeImmune Inc. (NASDAQ:GBIM). The therapy targets cancers that express carcinoembryonic antigen (CEA). GlobeImmune expects results in 2H16 from a...
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big cap...
BC Week In Review | Jun 15, 2015
Clinical News

GI-6301: Phase II started

GlobeImmune began the double-blind, U.S. Phase II GI-6301-02 trial to evaluate subcutaneous GI-6301 plus radiotherapy in about 50 patients. Patients will receive 3 doses of GI-6301 or placebo given 2 weeks apart prior to radiotherapy....
BC Week In Review | Jun 15, 2015
Company News

GlobeImmune infectious news

GlobeImmune will cut the “majority” of its headcount to save cash after GS-4774 missed the primary endpoint in the Phase II GS-US-330-0101 trial to treat chronic HBV infection in May. At Dec. 31, 2014, GlobeImmune...
BC Week In Review | Jun 1, 2015
Clinical News

GS-4774: Phase II data

Top-line data from the open-label, U.S. and New Zealand Phase II GS-US-330-0101 trial in 178 virally suppressed patients with chronic HBV infection showed that 40 yeast units of subcutaneous GS-4774 once monthly plus ongoing oral...
Items per page:
1 - 10 of 103
BC Extra | Jul 31, 2019
Company News

Apelian to lead new T cell company BlueSphere

With serial biotech executive David Apelian as CEO, University of Pittsburgh and UPMC spinout BlueSphere debuted Wednesday with plans to move its personalized T cell therapies into the clinic. Pitt professors Mark and Warren Shlomchik,...
BC Extra | Nov 18, 2016
Company News

Gilead ends GlobeImmune HBV deal

GlobeImmune Inc. (Pink:GMIB) said Gilead Sciences Inc. (NASDAQ:GILD) returned rights to HBV candidate GS-4774 and terminated a 2011 partnership to develop HBV vaccines. The companies had hoped to create vaccines based on GlobeImmune's Tarmogen products,...
BC Week In Review | Nov 18, 2016
Company News

Gilead, GlobeImmune deal

GlobeImmune said Gilead terminated a 2011 deal granting Gilead rights to GS-4774 . GlobeImmune regained all rights to the product. GS-4774, a Tarmogen comprising a heat-inactivated Saccharomyces cerevisiae that expresses HBV antigens, missed the primary endpoint...
BC Week In Review | Sep 21, 2015
Company News

GlobeImmune cancer news

In August, GlobeImmune hired Cantor Fitzgerald & Co. to evaluate strategic options, including a merger or sale of all or part of the company. Earlier this year, Celgene Corp. (NASDAQ:CELG, Summit, N.J.) exercised its option...
BC Week In Review | Aug 10, 2015
Company News

GlobeImmune, Celgene deal

Celgene exercised its option under an 2009 deal and received exclusive, worldwide rights to oncology candidate GI-6207 from GlobeImmune. GlobeImmune will receive a $1.9 million option exercise fee and is eligible for undisclosed regulatory and...
BC Extra | Aug 4, 2015
Company News

Celgene licenses GlobeImmune cancer candidate

Celgene Corp. (NASDAQ:CELG) exercised its option to license exclusive, worldwide rights to oncology candidate GI-6207 from GlobeImmune Inc. (NASDAQ:GBIM). The therapy targets cancers that express carcinoembryonic antigen (CEA). GlobeImmune expects results in 2H16 from a...
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big cap...
BC Week In Review | Jun 15, 2015
Clinical News

GI-6301: Phase II started

GlobeImmune began the double-blind, U.S. Phase II GI-6301-02 trial to evaluate subcutaneous GI-6301 plus radiotherapy in about 50 patients. Patients will receive 3 doses of GI-6301 or placebo given 2 weeks apart prior to radiotherapy....
BC Week In Review | Jun 15, 2015
Company News

GlobeImmune infectious news

GlobeImmune will cut the “majority” of its headcount to save cash after GS-4774 missed the primary endpoint in the Phase II GS-US-330-0101 trial to treat chronic HBV infection in May. At Dec. 31, 2014, GlobeImmune...
BC Week In Review | Jun 1, 2015
Clinical News

GS-4774: Phase II data

Top-line data from the open-label, U.S. and New Zealand Phase II GS-US-330-0101 trial in 178 virally suppressed patients with chronic HBV infection showed that 40 yeast units of subcutaneous GS-4774 once monthly plus ongoing oral...
Items per page:
1 - 10 of 103